BIO TECHS?!?!Another classic set up that was been constantly rewarding investors long the risk reversal trade. Sector was been showing strength as you go down the cap scale.
high and tight holds probably
−0.30USD
−66.07 MUSD
124.46 MUSD
223.69 M
About Ardelyx, Inc.
Sector
CEO
Michael G. Raab
Headquarters
Waltham
Website
Employees (FY)
267
Founded
2007
ISIN
US0396971071
FIGI
BBG001WH4DQ3
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
ARDX Ardelyx Options Ahead of Earnings If you haven`t bought ARDS before it went up 6X:
Then analyzing the options chain and the chart patterns of ARDX Ardelyx prior to the earnings report this week,
I would consider purchasing the 4usd strike price Calls with
an expiration date of 2024-1-19,
for a premium of approximately $0.45.
If t
Focus on Biotechnology: Ardelyx Inc. Trading Idea for 19/10/2023Biotechnology company Ardelyx Inc. has received FDA approval for its drug Xphozah. This medication is intended for treating kidney diseases and is typically recommended for patients with elevated kidney phosphorus levels. Xphozah could be a valuable addition to hemodialysis therapy since it is compa
ARDX: Buy ideaBuy idea on ARDX as you see on the chart after the breakout with force the vwap indicator and the resistance line by a big green candle with a large green volume. In other hand, we will have a reversal trend if we have the breakout with force the support line by a big red candle with a large red vol
ARDX Strong upgrade from a top financial firmARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally.
On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $
ARDXLooking at 1-hour chart
hit resistant of 2.80
Pulling back
Looking for an entry around 2.63
Potential Gap UP
Cup and handle formation?Breakout above 2.2? and possible gap fill toward upside.
The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9:4, with the majority favoring treatment with the drug as monotherapy.
FDA decision soon. Risk is traditional sell the news event.
ARDX | InformativeNASDAQ:ARDX
If it passes the bearish line it's time for a short position, and if it passes the bullish line it's time for the Long position, the price targets are on the chart.
$ARDX textbook wedge This trade is not actionable without volume confirmation, wedge breakout, and ofc a SET SL AND TP
ALSO looking at GAP fill over $2.00+
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ARDX is 6.44 USD — it has decreased by 1.68% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ardelyx, Inc. stocks are traded under the ticker ARDX.
Ardelyx, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
ARDX stock is 2.74% volatile and has beta coefficient of 2.28. Check out the list of the most volatile stocks — is Ardelyx, Inc. there?
One year price forecast for Ardelyx, Inc. has a max estimate of 16.00 USD and a min estimate of 11.00 USD.
ARDX earnings for the last quarter are 0.03 USD per share, whereas the estimation was −0.11 USD resulting in a 127.89% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about Ardelyx, Inc. earnings.
Ardelyx, Inc. revenue for the last quarter amounts to 56.39 M USD despite the estimated figure of 22.57 M USD. In the next quarter revenue is expected to reach 34.06 M USD.
Yes, you can track Ardelyx, Inc. financials in yearly and quarterly reports right on TradingView.
ARDX stock has fallen by 10.18% compared to the previous week, the month change is a 17.22% fall, over the last year Ardelyx, Inc. has showed a 33.61% increase.
ARDX net income for the last quarter is −28.80 M USD, while the quarter before that showed 6.63 M USD of net income which accounts for −534.48% change. Track more Ardelyx, Inc. financial stats to get the full picture.
Today Ardelyx, Inc. has the market capitalization of 1.50 B, it has decreased by 0.27% over the last week.
No, ARDX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ARDX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ardelyx, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 267.00 employees. See our rating of the largest employees — is Ardelyx, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ardelyx, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ardelyx, Inc. stock shows the buy signal. See more of Ardelyx, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Ardelyx, Inc. future price: according to them, ARDX price has a max estimate of 16.00 USD and a min estimate of 11.00 USD. Read a more detailed Ardelyx, Inc. forecast: see what analysts think of Ardelyx, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ardelyx, Inc. EBITDA is −59.29 M USD, and current EBITDA margin is −49.80%. See more stats in Ardelyx, Inc. financial statements.